Abstracts Archive - Page 2084 of 2425 - ACR Meeting Abstracts

Abstract Number: 2526 • 2013 ACR/ARHP Annual Meeting
An Autoantibody Profile for The Diagnosis Of Systemic Lupus Erythematosus Using the IMMUNARRAY iCHIP™
Chaim Putterman¹, Irene Blanco², Nicole Jordan³, Yves Renaudineau⁴, Vered Daniel Carmi⁵, Rachel Sorek⁵, Ornit Cohen-Gindi⁵, Miriam Lerner⁵, D. Scott Batty⁵, Idan Tamir⁵ and Irun R Cohen^5,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Department of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁵ImmunArray, Rehovot, Israel, ⁶Immunology, Weizmann Institute of Science, Rehovot, Israel
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, recurrent, and potentially fatal multisystem inflammatory disorder mainly affecting women. SLE patients produce antibodies to many different self-antigens,…
Abstract Number: 2527 • 2013 ACR/ARHP Annual Meeting
Association Of Nail Dystrophy With Capillaroscopic Abnormalities, Anti-Endothelial Cell Antibody, Endothelin-1, Activity and Chronicity In Systemic Lupus Erythematosus
Violeta Higuera¹, Luis M. Amezcua-Guerra², Felipe Massó³, Mariana Patlan⁴, Hugo Montoya⁵, Araceli Paez⁴ and Luis H. Silveira⁶, ¹Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ³Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁴Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁵Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ⁶Rheumatology, Instituto Nacional Cardiología Ignacio Chávez, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, characterized by a broad spectrum of clinical manifestations. There is a large…
Abstract Number: 2528 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcome In 69 Pregnancies Of Multinational Population In Qatar With Systemic Lupus Erythematosus
Abdul Razzakh Poil¹, Mohammed Hammoudeh¹, Prem Chandra², Abdo Lutf¹ and Samar AL Emadi^1,3, ¹Medicine/Rheumatology, Hamad General Hospital, Doha, Qatar, ²Medical Research Center, Hamad Medical Corporation, Doha, Qatar, ³Medicine, ASSISTANT proffesor of clinical medicine weill cornell medical school Qatar, Doha, Qatar
Background/Purpose: The aim of this study is to determine the frequencies of abnormal pregnancy outcomes in a cohort of patients in Qatar and to identify…
Abstract Number: 2529 • 2013 ACR/ARHP Annual Meeting
Improved Outcomes In High Risk Lupus Pregnancies: Usefulness Of a Protocol Based Multidisciplinary Approach In Kerala, India
Vinod Ravindran¹, S Bhadran², P Shyjus³, M Divakaran⁴ and V Reshma⁵, ¹Department of Rheumatology, MES Medical College, Kerala, INDIA, Perinthalmanna, India, ²Department of Obstetrics, National Hospital, Calicut, India, ³Department of Obstetrics, MES Medical College, Perinthalmanna, India, ⁴Department of Obstetrics, PVS Hospital, Calicut, India, ⁵Department of Obstetrics, Indira Gandhi Hospital, Thalassery, India
Background/Purpose: In patients with SLE who had previous adverse obstetric outcome(s) the risk of an adverse outcome in subsequent pregnancy rises. The primary objective of…
Abstract Number: 2530 • 2013 ACR/ARHP Annual Meeting
Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension
Vibeke Strand¹, Joan T. Merrill², Enkeleida Nikaï³, Brian Kilgallen⁴, Antoine Regnault⁵ and Caroline Gordon⁶, ¹Stanford University, Palo Alto, CA, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Raleigh, NC, ⁵Mapi HEOR & Strategic Market Access, Lyon, France, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. Improvements in health-related quality of life (HRQoL) with epratuzumab in patients with systemic lupus erythematosus (SLE) have…
Abstract Number: 2531 • 2013 ACR/ARHP Annual Meeting
Elevated Combined Serum Free Light Chains Are Associated With Active Disease In Systemic Lupus Erythematosus
Lakhvir Kaur Assi¹, Larissa Lisnevskaia², Emma Ross³, Richard G Hughes¹, Anisur Rahman⁴ and David A. Isenberg⁵, ¹Clinical R+D, The Binding Site Group Ltd, Birmingham, United Kingdom, ²Oshawa Clinic, Oshawa, ON, Canada, ³Centre for Rheumatology, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Chronic and hyper-stimulated B cells are characteristics commonly found in patients with systemic lupus erythematosus (SLE). Due to the complexity and variability observed during…
Abstract Number: 2492 • 2013 ACR/ARHP Annual Meeting
Functionally Distinct ERAP1 Haplotype Combinations Distinguish Individuals With Ankylosing Spondylitis
Edward James¹, Emma Reeves¹, Alexandra Colebatch², Tim Elliott¹ and Christopher J. Edwards³, ¹Cancer Sciences Unit, University of Southampton, Southampton, United Kingdom, ²Rheumatology, University Hospital Southampton, Southampton, United Kingdom, ³NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Background/Purpose: The association of Ankylosing Spondylitis (AS) with HLA-B27 has been known for many years. Recent genetic linkage studies have identified polymorphisms within the aminopeptidase,…
Abstract Number: 2493 • 2013 ACR/ARHP Annual Meeting
Interleukin-17 Serum Levels Are Associated With Markers Of Systemic Inflammation In Patients With Active Ankylosing Spondylitis
Denis Poddubnyy¹, Alain Vicari², Hildrun Haibel¹, Jürgen Braun³, Martin Rudwaleit⁴ and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²EMD Serono, Geneva, Switzerland, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Endokrinologikum, Berlin, Germany
Background/Purpose: There is accumulating evidence that the Th17-signaling axis, particularly interleukin-17 (IL-17), plays an important role in the pathogenesis of ankylosing spondylitis (AS). Furthermore, biologics…
Abstract Number: 2494 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Associated Endoplasmic Reticulum Aminopaptidase 1 Variants In Antigen Presentaing Cells Affect HLA-B27 Free Heavy Chain Expression and Binding To NK-Cell Receptors
Nigil Haroon^1,2,3 and Zhenbo Zhang³, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, ³Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: ERAP1 and HLA-B27 are strongly associated with ankylosing spondylitis (AS). Using well-controlled tissue culture systems, we studied the effects of AS-associated ERAP1 variants on…
Abstract Number: 2495 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis Protective Endoplasmic Reticulum Aminopeptidase 1 Variants Lead To Decreased Natural Killer Cell Conjugation and Activation
Hasan Abdullah¹, Zhenbo Zhang², Robert Inman³ and Nigil Haroon⁴, ¹IMS, University of Toronto, Toronto, ON, Canada, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada, ⁴Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory arthritis affecting the axial and peripheral joints. Human Leukocyte Antigen (HLA)-B27 and Endoplasmic Reticulum Aminopeptidase (ERAP) 1 genes…
Abstract Number: 2496 • 2013 ACR/ARHP Annual Meeting
HLA-B27 Influence On The Gut Microbiome
Robert D. Inman¹, Aifeng Lin², Phillip Sherman³ and Lee Pinnell⁴, ¹Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Medicine/Rheumatology, Toronto Western Research Institute and University Health Network, Toronto, ON, Canada, ³Pediatrics, Hospital for Sick Children, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The interrelationship between the gut microbiome and spondyloarthritis (SpA) has been highlighted by recent findings of (i) Subclinical bowel inflammation in SpA (ii) Antimicrobial…
Abstract Number: 2497 • 2013 ACR/ARHP Annual Meeting
Evidence Of a Microbial Signature In The Intestinal Microbiome In Ankylosing Spondylitis
Mary-Ellen Costello¹, Francesco Ciccia², Brooke Gardiner³, Mhairi Marshall³, Dana Willner⁴, Tony Kenna³, Giovanni Triolo² and Matthew A. Brown³, ¹Human Genetics Group, University of Queensland Diamantina Institute, Brisbane, Australia, ²Rheumatology Unit, University of Palermo, Palermo, Italy, ³University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australia
Background/Purpose: Ankylosing spondylitis (AS) occurs in genetically predisposed individuals exposed to an unknown but likely ubiquitous environmental trigger. In both AS and Crohn’s disease (CD)…
Abstract Number: 2498 • 2013 ACR/ARHP Annual Meeting
ERAP2 Functional Knockout In Humans Does Not Alter ER Stress Or Evidence Of HLA-B27 Misfolding In Ankylosing Spondylitis
Philip Robinson¹, Yang Wang², Eugene Lau², Patricia Keith², Tony Kenna³ and Matthew A. Brown³, ¹Human Genetics Group, University of Queensland Diamantina Insititute, Brisbane, Australia, ²Human Genetics Group, University of Queensland Diamantina Institute, Brisbane, Australia, ³University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: SNPs in ERAP2 are strongly associated with ankylosing spondylitis (AS). One associated SNP is rs2248374 which changes the strength of the exon 10 donor…
Abstract Number: 2499 • 2013 ACR/ARHP Annual Meeting
Analysis Of Inflammatory Markers Within Facet Joints Of Patients Within Ankylosing Spondylitis
Uta Syrbe¹, Janine Bleil², Rene Maier³, Heiner Appel¹ and Joachim Sieper⁴, ¹Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, ²Charité, Berlin, Germany, ³Charite, Berlin, Germany, ⁴Charitè Campus Benjamin Franklin, Berlin, Germany
Background/Purpose: Inflammation within sacroiliac joints and within the spine is a hallmark of ankylosing spondylitis (AS). Apart from nonsteroidal anti-rheumatic drug (NSAID) treatment, inhibition of…
Abstract Number: 2500 • 2013 ACR/ARHP Annual Meeting
Mast Cells Are a Major Source Of IL-17 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases
T. Noordenbos¹, I. Gofita¹, M. Alsina², E.W.M. Vogels³, A. A. te Velde³, J. D. Cañete⁴, Dominique L. Baeten⁵ and N. Yeremenko¹, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain, ³Tytgat Institute for Liver and Intestinal Research, Academic Medical Centre/University of Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Department of Clinical Immunology and Rheumatology Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17 plays a key role in the pathogenesis of spondyloarthritis (SpA) as demonstrated by a recent proof-of-concept trial with the anti-IL17A mAb secukinumab. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].